Pulnovo Medical
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $100M
Overview
A Chinese medtech leader developing catheter-based denervation therapies for pulmonary hypertension and heart failure.
CardiovascularPulmonary
Technology Platform
Catheter-based radiofrequency ablation platform for pulmonary artery denervation (PADN) to modulate sympathetic nervous system activity and reduce pulmonary vascular pressure.
Funding History
1Total raised:$100M
Strategic Investment$100M
Opportunities
Significant global market opportunity in pulmonary hypertension and heart failure, where PADN offers a novel interventional option alongside drugs; expansion into new geographies (US, Europe, Middle East) and potential label expansion into broader heart failure populations.
Risk Factors
Clinical and commercial execution risk in complex, procedure-driven markets; need to establish robust physician training and adoption; competition from established pharmaceutical therapies and potential future device-based competitors; regulatory and reimbursement hurdles in key markets like the US.
Competitive Landscape
PADN faces competition from established PH drug classes (endothelin receptor antagonists, PDE5 inhibitors, prostacyclins) and other device-based approaches under investigation. Its primary differentiation is its first-in-class status, strong clinical data package, and unique guideline endorsements for a device therapy in PH.